Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.

ABSTRACT:

Background

Data on integrase inhibitor resistance come primarily from clinical trials and in vitro studies. We examined results of all clinically indicated integrase genotypic resistance tests (GRTs) performed at a US national referral lab from 2009 through 2012.

Methods

Integrase sequences and demographic data were compiled with paired protease-reverse transcriptase (PR-RT) GRT results, when available. Analyses utilized the Stanford HIV Drug Resistance Database. "Major" integrase mutations included T66AIK, E92QV, F121Y, Y143CHR, S147G, Q148HKR, and N155H; multiple accessory mutations were also assessed.

Results

Among 3294 sequences from 3012 patients, 471 patients had viruses with ≥ 1 raltegravir or elvitegravir resistance mutation (15.6%). Q148 and N155 pathways wer

SUBMITTER: Hurt CB 

PROVIDER: S-EPMC3890334 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature